Compare Sunrun Inc (RUN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs BIO-TECHNE Corp — how do they compare? Sunrun Inc trades at $8.78 (market cap $2.12B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.33B). The key difference: BIO-TECHNE Corp is far larger — about 5.3× Sunrun Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| RUN | TECH | |
|---|---|---|
Market Cap | $2.12B | $11.33B |
Sector | Technology | Health |
52-Week High | $21.41 | $72.48 |
52-Week Low | $8.37 | $43.31 |
Enterprise Value | $16.64B | $11.35B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $9.22, up 3.71% today, but faces a bearish technical trend with resistance at $10. The company shows mixed fundamentals: it beat Q2 2026 EPS estimates ($0.42 actual vs. $0.23 expected) but cut full-year guidance, contributing to a 46% stock decline. Revenue is projected to grow to $3.5B in 2026, yet net income margin may drop to 11.59%. Recent news highlights a partnership with Voltus for AI hyperscaler energy capacity, offering a potential growth catalyst amid operational challenges.
The outlook is cautious; RUN appears undervalued with a P/E of 6.27 and P/B of 0.64, but risks include weak cash flow from operations (-$421M in 2025) and high debt. Analyst consensus is bullish (62% buy ratings) with a $14.70 price target, implying 59% upside, though execution on subscriber growth and margin recovery is critical for realizing gains.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
